| Akouos is a genetic medicine company, engaged in developing gene therapies to restore, improve, and preserve physiologic hearing for individuals who live with disabling hearing loss. Co. has a genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus used in gene therapy, known as adeno-associated virus, and a delivery approach. Co. is developing its product candidate, AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of etiology, such as AK-antiVEGF for vestibular schwannoma. We show 10 historical shares outstanding datapoints in our coverage of AKUS's shares outstanding history.|
Understanding the changing numbers of AKUS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AKUS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AKUS by allowing them to research AKUS shares outstanding history
as well as any other stock in our coverage universe.